<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627573</url>
  </required_header>
  <id_info>
    <org_study_id>06/15-n</org_study_id>
    <nct_id>NCT02627573</nct_id>
  </id_info>
  <brief_title>Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT</brief_title>
  <official_title>Randomized Trial of GVHD Prophylasxis With Post-transplantation Cyclophocphomide (PTCy) or Thymoglobulin in Unrelated SCT Recepients With Chronic Myeloproliferative Neoplasms and Myelodisplatic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose There is a growing evidence of high efficacy of post-transplantation cyclophocphomide
      (PTCy)-based GVHD prophylaxis in haploidentical and matched related and unrelated bone marrow
      transplantation. There is limitted, but growing data on safety and efficacy of this
      prophylaxis in unrelated and peripheral blood stem cell transplantations. Use of PTCy in
      chronic myeloproliferative neoplasms and myelodisplatic syndrome is of particular interest.
      On the one hand, PTCy could reduce the incidence of chronic GVHD and long-term bormidity. On
      the other hand, there is a concern, that PTCy can increase the incidence of graft failures in
      this group of patients. Currently published data indicate that low-dose Thymoglobulin-based
      prophylaxis is the most promissing compatitor in terms of acute and chronic GVHD control. So
      there is a rationale to randomize Thymoglobulin and PTCy as GVHD prophilaxis. Pre-transplant
      assesment of moratlity (PAM)-index will be used as the strata for randomization, as it is the
      paramter that takes into account the most important factors effecting survival. The
      conditioning regimen and the other two components of GVHD prophylaxis (mycophenolate mofetil
      and tacrolimus) will be identical in the two arms of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of primary graft failure</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute GVHD, grades II-IV</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD, moderate and severe (NIH criteria)</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate analysis</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (NCI CTCAE 4.03)</measure>
    <time_frame>100 days</time_frame>
    <description>Toxicity parameters based on NCI CTCAE 4.03 grades: hepatotoxicity (liver function tests), nephrotoxicity (creatinine), neurotoxicity (attending physician assessment), mucositis (attending physician assessment), hemorrhagic cystitis (attending physician assessment), cardiotoxicity (ECG, echocardiography). Additional toxicity parameters: incidence and severity of veno-occlusive disease, incidence of transplant-associated microangiopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious complications, including analysis of severe bacterial, fungal and viral infections incidence</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Leukemia, Chronic Myeloid</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative</condition>
  <arm_group>
    <arm_group_label>Thymoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -5 Busulfan 1 mg/kg po qid x 2 days Days -4 through -3 Thymoglobulin 2,5 mg/kg po qd x 2 days Days -1 through +30: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days -1 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTCy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Unrelated allogeneic stem cell transplantation</intervention_name>
    <arm_group_label>Thymoglobulin</arm_group_label>
    <arm_group_label>PTCy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <arm_group_label>Thymoglobulin</arm_group_label>
    <arm_group_label>PTCy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine monophosphate</intervention_name>
    <arm_group_label>Thymoglobulin</arm_group_label>
    <arm_group_label>PTCy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <arm_group_label>Thymoglobulin</arm_group_label>
    <arm_group_label>PTCy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <arm_group_label>Thymoglobulin</arm_group_label>
    <arm_group_label>PTCy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>PTCy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <arm_group_label>Thymoglobulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have an indication for allogeneic hematopoietic stem cell
             transplantation

          -  Diagnosis: Chronic myeloid leukemia Myelodysplastic Syndromes Myeloprolipherative
             neoplsm unclassified Atypical chronic myelogenous leukemia

          -  Signed informed consent

          -  Patients with 10/10 HLA-matched unrelated donor available. The donor and recipient
             must be identical by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and
             HLA-DQB1. Mismatches in these loci are not allowed.

          -  Peripheral blood stem cells as graft source

          -  No second tumors

          -  No prior history of Thymoglobulin exposure or no history of anaphylactic shock after
             Thymoglobulin administration

          -  No severe concurrent illness

        Exclusion Criteria:

          -  Moderate or severe cardiac dysfunction, left ventricular ejection fraction &lt;50%

          -  Moderate or severe decrease in pulmonary function, FEV1 &lt;70% or DLCO&lt;70% of predicted

          -  Respiratory distress &gt;grade I

          -  Severe organ dysfunction: AST or ALT &gt;5 upper normal limits, bilirubin &gt;1.5 upper
             normal limits, creatinine &gt;2 upper normal limits

          -  Creatinine clearance &lt; 60 mL/min

          -  Uncontrolled bacterial or fungal infection at the time of enrollment

          -  Requirement for vasopressor support at the time of enrollment

          -  Karnofsky index &lt;30%

          -  Pregnancy

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris V. Afanasyev, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Pavlov State Medical University of St. Petersburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivan S. Moiseev, PhD</last_name>
    <phone>+79217961951</phone>
    <email>moisiv@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Boris V. Afanasyev, Professor</last_name>
    <phone>+78122334551</phone>
    <email>coordinatorbmt@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan S. Moiseev, PhD</last_name>
      <phone>+79217961951</phone>
      <email>moisiv@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>Boris V. Afanasyev, Professor</last_name>
      <phone>+78122334551</phone>
      <email>coordinatorbmt@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Petersburg State Pavlov Medical University</investigator_affiliation>
    <investigator_full_name>Ivan S Moiseev</investigator_full_name>
    <investigator_title>Head of adolescent and adult department of oncology, heamatology and transplantation</investigator_title>
  </responsible_party>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Thymoglobulin</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <keyword>Antineoplastic Agents, Alkylating</keyword>
  <keyword>Myeloablative Agonists</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Allogeneic Transplantation</keyword>
  <keyword>Leukemia, Chronic Myeloid</keyword>
  <keyword>Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Antineoplastic Agents, Alkylating</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

